Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Roy M Fleischmann"'
Autor:
Roy M. Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-11 (2021)
Abstract Background/objective REFLECTIONS B538–02 is a randomized, double-blind comparative study of the adalimumab (ADL) biosimilar PF-06410293, (ADL-PF), and reference ADL sourced from the European Union (ADL-EU) in patients with active RA. Thera
Externí odkaz:
https://doaj.org/article/0ee2953ecc944c48b52581e98907ed2d
Autor:
Eugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann
Publikováno v:
Modern Rheumatology Journal. 17:23-26
ObjectivesTo assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).MethodsI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da1b928747915d791bf834ce64c4d62
https://doi.org/10.14412/1996-7012-2023-2-23-36
https://doi.org/10.14412/1996-7012-2023-2-23-36
Autor:
Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira®)
Externí odkaz:
https://doaj.org/article/1d4bd355220e4ba2b38cbe7e573f3370
Autor:
Roy M. Fleischmann, Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger, Eva Dokoupilová
Publikováno v:
Rheumatology and Therapy. 9:839-850
The aim of this sub-study was to evaluate injection success of patients with rheumatoid arthritis (RA) and their caregivers administering the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF: adalimumab-afzb; AbriladaThis sub-study included adult pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c58f54ca73100780cd84f9a908a6a456
https://doi.org/10.1007/s40744-022-00439-8
https://doi.org/10.1007/s40744-022-00439-8
Autor:
Josef S, Smolen, Eugen, Feist, Saeed, Fatenejad, Sergey A, Grishin, Elena V, Korneva, Evgeniy L, Nasonov, Mikhail Y, Samsonov, Roy M, Fleischmann, Marina, Stanislav
Publikováno v:
The New England journal of medicine. 387(8)
The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.In a 24-week, pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44db234971c7ad5f5b2c9ca44aec5ed
https://pubmed.ncbi.nlm.nih.gov/36001712
https://pubmed.ncbi.nlm.nih.gov/36001712
Autor:
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Publikováno v:
Annals of the rheumatic diseases. BMJ
Aletaha, D, Kerschbaumer, A, Kastrati, K, Dejaco, C, Dougados, M, McInnes, I B, Sattar, N, Stamm, T A, Takeuchi, T, Trauner, M, van der Heijde, D S, Voshaar, M, Winthrop, K L, Ravelli, A, Betteridge, N, Burmester, G-R D R, Bijlsma, J W J, Bykerk, V, Caporali, R, Choy, E H, Codreanu, C, Combe, B, Crow, M K, de Wit, M, Emery, P, Fleischmann, R M, Gabay, C, Hetland, M L, Hyrich, K L, Iagnocco, A, Isaacs, J D, Kremer, J M, Mariette, X, Merkel, P, Mysler, E F, Nash, P, Nurmohamed, M T, Pavelka, K, Poor, G, Rubbert-Roth, A, Schulze-Koops, H, Strangfeld, A, Tanaka, Y & Smolen, J S 2022, ' Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions : an update ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/ard-2022-222784
Annals of the Rheumatic Diseases. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases
Aletaha, D, Kerschbaumer, A, Kastrati, K, Dejaco, C, Dougados, M, McInnes, I B, Sattar, N, Stamm, T A, Takeuchi, T, Trauner, M, Van Der Heijde, D, Voshaar, M, Winthrop, K L, Ravelli, A, Betteridge, N, Burmester, G R R, Bijlsma, J W J, Bykerk, V, Caporali, R, Choy, E H, Codreanu, C, Combe, B, Crow, M K, De Wit, M, Emery, P, Fleischmann, R M, Gabay, C, Hetland, M L, Hyrich, K L, Iagnocco, A, Isaacs, J D, Kremer, J M, Mariette, X, Merkel, P, Mysler, E F, Nash, P, Nurmohamed, M T, Pavelka, K, Poor, G, Rubbert-Roth, A, Schulze-Koops, H, Strangfeld, A, Tanaka, Y & Smolen, J S 2023, ' Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions : an update ', Annals of the Rheumatic Diseases, vol. 82, no. 6, pp. 773–787 . https://doi.org/10.1136/ard-2022-222784
Annals of the Rheumatic Diseases. BMJ Publishing Group
Aletaha, D, Kerschbaumer, A, Kastrati, K, Dejaco, C, Dougados, M, McInnes, I B, Sattar, N, Stamm, T A, Takeuchi, T, Trauner, M, van der Heijde, D S, Voshaar, M, Winthrop, K L, Ravelli, A, Betteridge, N, Burmester, G-R D R, Bijlsma, J W J, Bykerk, V, Caporali, R, Choy, E H, Codreanu, C, Combe, B, Crow, M K, de Wit, M, Emery, P, Fleischmann, R M, Gabay, C, Hetland, M L, Hyrich, K L, Iagnocco, A, Isaacs, J D, Kremer, J M, Mariette, X, Merkel, P, Mysler, E F, Nash, P, Nurmohamed, M T, Pavelka, K, Poor, G, Rubbert-Roth, A, Schulze-Koops, H, Strangfeld, A, Tanaka, Y & Smolen, J S 2022, ' Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions : an update ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/ard-2022-222784
Annals of the Rheumatic Diseases. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases
Aletaha, D, Kerschbaumer, A, Kastrati, K, Dejaco, C, Dougados, M, McInnes, I B, Sattar, N, Stamm, T A, Takeuchi, T, Trauner, M, Van Der Heijde, D, Voshaar, M, Winthrop, K L, Ravelli, A, Betteridge, N, Burmester, G R R, Bijlsma, J W J, Bykerk, V, Caporali, R, Choy, E H, Codreanu, C, Combe, B, Crow, M K, De Wit, M, Emery, P, Fleischmann, R M, Gabay, C, Hetland, M L, Hyrich, K L, Iagnocco, A, Isaacs, J D, Kremer, J M, Mariette, X, Merkel, P, Mysler, E F, Nash, P, Nurmohamed, M T, Pavelka, K, Poor, G, Rubbert-Roth, A, Schulze-Koops, H, Strangfeld, A, Tanaka, Y & Smolen, J S 2023, ' Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions : an update ', Annals of the Rheumatic Diseases, vol. 82, no. 6, pp. 773–787 . https://doi.org/10.1136/ard-2022-222784
Annals of the Rheumatic Diseases. BMJ Publishing Group
BackgroundTargeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5450f45d4f38f87158cb07200a3b129
https://doi.org/10.1136/ard-2022-222784
https://doi.org/10.1136/ard-2022-222784
Autor:
Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan J Kivitz, Robert J Moots, Zhen Luo, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Svitlana Tatulych, Christopher Mojcik, Sriram Krishnaswami, Sujatha Menon, Josef S Smolen, Luthando Adams, Mahmood M Ally, Maria C du Plooy, Ingrid C Louw, Savithree Nayiager, Christoffel B Nel, Debra Nel, Helmuth Reuter, Ahmed S Soloman, Catherine E Spargo, Maureen Rischmueller, Shunil D Sharma, Robert K Will, Peter P Youssef, Caroline Arroyo, Rosario P Baes, Roger B Dulos, Llewellyn T Hao, Allan E Lanzon, Juan Javier T Lichauco, Jill H Mangubat, Edgar B Ramiterre, Bernadette Heizel M Reyes, Perry P Tan, Jung-Yoon Choe, Young Mo Kang, Seong Ryul Kwon, Sang-Heon Lee, Shin-Seok Lee, Dae-Hyun Yoo, Hsiao-Yi Lin, Shue-Fen Luo, Shih-Tzu Tsai, Wen-Chan Tsai, Jui-Cheng Tseng, Cheng-Chung C Wei, Paijit Asavatanabodee, Kanokrat Nantiruj, Surasak Nilganuwong, Parichat Uea-Areewongsa, Ljubinka Bozic Majstorovic, Suada Mulic Bacic, Anastas Z Batalov, Gabriela Georgieva-Slavcheva, Mariyana Mihailova, Nikolay G Nikolov, Dimitar P Penev, Yuliy A Spasov, Krasimira Stanimirova, Stoyan Todorov, Antoaneta R Toncheva, Nadezhda Yordanova, Zdenka Mosterova, Libor Novosad, Leona Prochazkova, Helena Stehlikova, Zuzana Stejfova, Natalia Kiseleva, Lea Pank, Triin Savi, Balbir-Gurman Alexandra, Howard Amital, Dror Mevorach, Itzhak A Rosner, Anna Mihailova, Evija Stumbra-Stumberga, Vida Basijokiene, Virginija Lietuvininkiene, Dalia Unikiene, Jan Brzezicki, Anna M Dudek, Maria B Glowacka-Kulesz, Barbara Grabowicz-Wasko, Sabina Hajduk-Kubacka, Joanna Hilt, Pawel Hrycaj, Slawomir Jeka, Renata Kolasa, Marek Krogulec, Hanna Mastalerz, Anna Olak-Popko, Elzbieta Owczarek, Zofia Ruzga, Alina Walczak, Codrina I Ancuta, Ioan Ancuta, Andra R Balanescu, Florian Berghea, Silvia Bojin, Mihaela A Ianuli Arvunescu, Ruxandra M Ionescu, Eugenia Mociran, Mariana Pavel, Simona Rednic, Adriana Voie, Carmen M Zainea, Olga V Bugrova, Alexander Demin, Olga B Ershova, Inna A Gavrisheva, Diana G Krechikova, Gennady V Kuropatkin, Irina M Marusenko, Irina V Menshikova, Sergey M Noskov, Andrey P Rebrov, Svetlana A Smakotina, Sergey S Yakushin, Evgeny Zhilyaev, Juan Jose Amarelo Ramos, Francisco Javier Blanco Garcia, Antonio Fernandez Nebro, Silvia Perez Esteban, Juan Miguel Sanchez Burson, Raimon Sanmarti Sala, Sebnem Ataman, Sami Hizmetli, Omer Kuru, Karen M Douglas, Paul Emery, Voon H Ong, Thomas P Sheeran, Rafat Y Faraawi, Clode Lessard, Carlos Abud Mendoza, Hilario Ernesto Avila-Armengol, Francisco I Avila Zapata, Fedra Consuelo Irazoque-Palazuelos, Marco Antonio Maradiaga Cecena, Cesar F Pacheco-Tena, Juan C Rizo-Rodriguez, Isaura M Rodriguez-Torres, Jacob A Aelion, Barbara A Caciolo, James M Calmes, Prem Chatpar, Nimesh Dayal, Alex De Jesus, Ara H Dikranian, Erdal Diri, Michael J Fairfax, Ira F Fenton, Roy M Fleischmann, Norman B Gaylis, Ronald L George, Dale G Halter, Paul Hernandez, Susan A Hole, Antony C Hou, John P Huff, Suzanne Kafaja, Alastair C Kennedy, Howard Kenney, Steven C Kimmel, Brian S Kirby, Clarence W Legerton, Stephen M Lindsey, Jyothi R Mallepalli, Steven D Mathews, Samy K Metyas, Wesley T Mizutani, Sabeen Najam, Joao M Nascimento, Shirley W Pang, Rakesh C Patel, Jeffrey E Poiley, Carlos E Ramirez, Riteesha Reddy, Qaiser Rehman, William M Schnitz, Craig D Scoville, William J Shergy, Joel C Silverfield, Atul K Singhal, Yvonne R Smallwood-Sherrer, Suthin N Songcharoen, Michael T Stack, William Stohl, Tien-I K Su, James Udell, Saleem Waraich, Charles E Weidmann, Nathan Wei, Craig W Wiesenhutter, Anne E Winkler, Karen E Zagar, Alberto Berman, Eduardo F Mysler, Rodolfo A Pardo Hidalgo, Horacio O Venarotti, Irmgadt Annelise Goecke Sariego, Renato E Jimenez Calabresse, Juan Ignacio Vargas Ruiz-Tagle, Luis Fernando M Bellatin Vargas, Alfredo E Berrocal, Manuel Gustavo Leon Portocarrero, Felix Jesus, Romero Pena
Publikováno v:
LANCET
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8d20ced5063ec70967b828d0b5d348d
https://pubmed.ncbi.nlm.nih.gov/28680135
https://pubmed.ncbi.nlm.nih.gov/28680135
Autor:
Joel M, Kremer, Ricardo, Blanco, Anne-Marie, Halland, Marek, Brzosko, Ruben, Burgos-Vargas, Christopher M, Mela, Lucy, Rowell, Roy M, Fleischmann
Publikováno v:
Clinical and experimental rheumatology. 34(4)
To report 5-year efficacy and safety in rheumatoid arthritis (RA) patients with active disease treated with tocilizumab.LITHE was a 2-year, randomised, placebo-controlled study of tocilizumab in RA patients (ClinicalTrials.gov, NCT00106535), with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8a60b71c02ed2509ec5b1a7e568628b6
https://pubmed.ncbi.nlm.nih.gov/27087059
https://pubmed.ncbi.nlm.nih.gov/27087059
Autor:
Stanley B, Cohen, Andrew, Koenig, Lisy, Wang, Kenneth, Kwok, Charles A, Mebus, Richard J, Riese, Roy M, Fleischmann
Publikováno v:
Clinical and experimental rheumatology. 34(1)
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. This post-hoc pooled analysis assessed commonalities and differences in tofacitinib efficacy and safety for US versus rest of the world (ROW) populations.Pooled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9340cb825f5b6370226e55b42d8cf324
https://pubmed.ncbi.nlm.nih.gov/26575982
https://pubmed.ncbi.nlm.nih.gov/26575982
Autor:
Roy M Fleischmann
Publikováno v:
Therapy. 1:255-266
Interleukin (IL)-1 is a primary mediator in the pathophysiology of rheumatoid arthritis. Elevated IL-1 levels have been detected in the synovium of patients with rheumatoid arthritis and such elevated levels have been correlated with disease severity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2574851e1cce21257acb27b2c336da
https://doi.org/10.2217/14750708.1.2.255
https://doi.org/10.2217/14750708.1.2.255